TRCT
SRPT icon

Tower Research Capital (TRC)’s Sarepta Therapeutics SRPT Stock Holding History

Tower Research Capital (TRC)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.2K Sell
4,243
-472
-10% -$8.93K ﹤0.01% 2399
2026
Q1 		$103K Buy
4,715
+2,669
+130% +$51.7K ﹤0.01% 2159
2025
Q4 		$44K Sell
2,046
-1,029
-33% -$21.7K ﹤0.01% 2518
2025
Q3 		$59.3K Sell
3,075
-192
-6% -$3.42K ﹤0.01% 2395
2025
Q2 		$55.9K Sell
3,267
-397
-11% -$16.9K ﹤0.01% 2879
2025
Q1 		$234K Sell
3,664
-10,858
-75% -$1.14M 0.01% 1280
2024
Q4 		$1.77M Buy
14,522
+5,371
+59% +$658K 0.04% 403
2024
Q3 		$1.14M Buy
9,151
+5,844
+177% +$808K 0.03% 489
2024
Q2 		$523K Buy
3,307
+2,293
+226% +$295K 0.01% 1298
2024
Q1 		$131K Buy
1,014
+275
+37% +$33.7K ﹤0.01% 1680
2023
Q4 		$71.3K Sell
739
-4,500
-86% -$432K ﹤0.01% 2899
2023
Q3 		$635K Buy
5,239
+2,326
+80% +$263K 0.02% 743
2023
Q2 		$334K Sell
2,913
-1,710
-37% -$221K 0.01% 1233
2023
Q1 		$637K Buy
4,623
+1,724
+59% +$224K 0.02% 699
2022
Q4 		$376K Buy
2,899
+2,316
+397% +$268K 0.02% 875
2022
Q3 		$65K Sell
583
-15,403
-96% -$1.55M ﹤0.01% 2926
2022
Q2 		$1.2M Buy
15,986
+3,531
+28% +$260K 0.03% 593
2022
Q1 		$973K Buy
12,455
+6,116
+96% +$468K 0.01% 797
2021
Q4 		$571K Buy
6,339
+4,297
+210% +$367K 0.01% 1024
2021
Q3 		$189K Sell
2,042
-2,909
-59% -$224K ﹤0.01% 1874
2021
Q2 		$385K Buy
4,951
+3,998
+420% +$303K 0.01% 1394
2021
Q1 		$71K Sell
953
-3,117
-77% -$288K ﹤0.01% 2845
2020
Q4 		$694K Sell
4,070
-1,099
-21% -$163K 0.02% 751
2020
Q3 		$726K Buy
5,169
+4,764
+1,176% +$724K 0.01% 1287
2020
Q2 		$65K Buy
+405
New +$55.1K ﹤0.01% 2848
2020
Q1 		– Sell
-970
Closed -$125K – 3838
2019
Q4 		$125K Buy
970
+345
+55% +$34.8K 0.01% 820
2019
Q3 		$47K Buy
+625
New +$73.8K ﹤0.01% 1840
2019
Q2 		– Sell
-7
Closed -$1K – 4248
2019
Q1 		$1K Sell
7
-230
-97% -$29.6K ﹤0.01% 3619
2018
Q4 		$26K Buy
237
+7
+3% +$875 ﹤0.01% 1743
2018
Q3 		$37K Buy
+230
New +$31.4K ﹤0.01% 1953
2018
Q1 		– Sell
-61
Closed -$3K – 3789
2017
Q4 		$3K Buy
61
+17
+39% +$901 ﹤0.01% 3106
2017
Q3 		$2K Buy
+44
New +$1.76K ﹤0.01% 3589
2017
Q1 		– Sell
-4,811
Closed -$132K – 3864
2016
Q4 		$132K Buy
4,811
+3,587
+293% +$144K 0.01% 835
2016
Q3 		$75K Buy
1,224
+107
+10% +$3.23K 0.01% 947
2016
Q2 		$21K Buy
+1,117
New +$20.7K ﹤0.01% 2197
2016
Q1 		– Sell
-353
Closed -$6.17K – 4880
2015
Q4 		$14K Sell
353
-2,145
-86% -$69.5K ﹤0.01% 1716
2015
Q3 		$81K Buy
2,498
+1,871
+298% +$63.5K 0.01% 689
2015
Q2 		$19K Sell
627
-7,418
-92% -$152K ﹤0.01% 2142
2015
Q1 		$107K Buy
8,045
+7,581
+1,634% +$101K 0.01% 831
2014
Q4 		$7K Buy
+464
New +$7.86K ﹤0.01% 2470
2014
Q1 		– Sell
-118
Closed -$2K – 4899
2013
Q4 		$2K Sell
118
-1,272
-92% -$37.8K ﹤0.01% 4047
2013
Q3 		$66K Sell
1,390
-951
-41% -$36.6K 0.01% 1661
2013
Q2 		$89K Buy
+2,341
New +$83.7K 0.01% 565

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Tower Research Capital (TRC)'s SRPT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Sarepta Therapeutics (SRPT) stake by 10% in Q2 2026, selling an estimated $8.93K and leaving 4,243 shares worth $76.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Tower Research Capital (TRC) first reported a position in SRPT in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.77M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Tower Research Capital (TRC) held 4,243 shares of Sarepta Therapeutics worth $76.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 472 Sarepta Therapeutics shares in Q2 2026, an estimated $8.93K.
  • Sarepta Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2399 holding.
  • Tower Research Capital (TRC) first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s Sarepta Therapeutics position peaked at $1.77M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.